Tags

Type your tag names separated by a space and hit enter

Glucagon-like Peptide-1 Receptor Agonists

Abstract
Glucagon-like peptide-1 (GLP-1) agonists represent a class of medications used in the treatment of type 2 diabetes mellitus in adults. Examples of drugs in this class include exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, and semaglutide. According to the American Diabetes Association, metformin remains the preferred first-line therapy for the treatment of type 2 diabetes. However, the addition of a GLP-1 analog should be considered in patients with a contraindication or intolerance to metformin, in patients with a hemoglobin A1c greater than 1.5% over target, or in patients who do not reach their target A1c in three months particularly in patients with atherosclerosis, heart failure, or chronic kidney disease.[1][2][3][4] Furthermore, high dose liraglutide is FDA approved as a pharmacologic treatment for obesity or can be prescribed to overweight patients with comorbidities. The utilization of GLP-1 analogs is an object of research with favorable hemoglobin A1c results and weight loss results in patients with type-1 diabetes mellitus. Of note, higher costs, as well as tolerability, remain significant barriers in prescribing these medications.[5][6][7][8]

Publisher

StatPearls Publishing
Treasure Island (FL)

Language

eng

PubMed ID

31855395

Citation

Collins L, Costello RA: Glucagon-like Peptide-1 Receptor Agonists. StatPearls. StatPearls Publishing, 2020, Treasure Island (FL).
Collins L, Costello RA. Glucagon-like Peptide-1 Receptor Agonists. StatPearls. StatPearls Publishing; 2020.
Collins L & Costello RA. (2020). Glucagon-like Peptide-1 Receptor Agonists. In StatPearls. Treasure Island (FL): StatPearls Publishing
Collins L, Costello RA. Glucagon-like Peptide-1 Receptor Agonists. StatPearls. Treasure Island (FL): StatPearls Publishing; 2020.
* Article titles in AMA citation format should be in sentence-case
TY - CHAP T1 - Glucagon-like Peptide-1 Receptor Agonists BT - StatPearls A1 - Collins,Logan, AU - Costello,Ryan A., Y1 - 2020/01// PY - 2019/12/20/pubmed PY - 2019/12/20/medline PY - 2019/12/20/entrez N2 - Glucagon-like peptide-1 (GLP-1) agonists represent a class of medications used in the treatment of type 2 diabetes mellitus in adults. Examples of drugs in this class include exenatide, lixisenatide, liraglutide, albiglutide, dulaglutide, and semaglutide. According to the American Diabetes Association, metformin remains the preferred first-line therapy for the treatment of type 2 diabetes. However, the addition of a GLP-1 analog should be considered in patients with a contraindication or intolerance to metformin, in patients with a hemoglobin A1c greater than 1.5% over target, or in patients who do not reach their target A1c in three months particularly in patients with atherosclerosis, heart failure, or chronic kidney disease.[1][2][3][4] Furthermore, high dose liraglutide is FDA approved as a pharmacologic treatment for obesity or can be prescribed to overweight patients with comorbidities. The utilization of GLP-1 analogs is an object of research with favorable hemoglobin A1c results and weight loss results in patients with type-1 diabetes mellitus. Of note, higher costs, as well as tolerability, remain significant barriers in prescribing these medications.[5][6][7][8] PB - StatPearls Publishing CY - Treasure Island (FL) UR - https://www.unboundmedicine.com/medline/citation/31855395/StatPearls:_Glucagon-like_Peptide-1_Receptor_Agonists L2 - https://www.ncbi.nlm.nih.gov/books/NBK551568 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.